Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity
What they found: Mean weight loss: 2.6 kg vs 2.3 kg placebo , a difference of only 0.3 kg (1 %) Statistically non-significant Clinically unsatisfactory for the obesity indication Safety profile remained favorable Why it matters: The study stopped the development of AOD-9604 as a drug
In Annals of Pharmacotherapy
These cholesterol reductions brought levels comparable to those seen in lean, healthy control mice, suggesting comprehensive metabolic normalization
Depending on the skin color, medium brown skin requires one to three months, and dark skin requires more than two years of treatment
Sun XS, Jang MS, Fu Y, Lee JH, Lee DS, Li Y, et al